Stock News

The Oct. 5 release says Galam's first doré bar came from Merrill-Crowe cement, but gives neither the bar's weight nor a date for the pilot to reach nameplate capacity.

The second 500 MW phase is now planned for 2029, but Kentucky commission approval and the utility's construction schedule still govern delivery.

Stoke plans to combine four Vineland-3 subdomains for its U.S. NDA after a Phase 3 readout expected in the third quarter of 2027.

The three holes totalled 1,076.9 metres in Akyanga's northeastern zone and will inform targeting for a second drilling phase.

The vaccine met the stricter direct test for 17 of 19 serotypes shared with Capvaxive, with two meeting an older threshold.

The Reykjavik approval doubles drug substance capacity available for U.S. supply; separate biosimilar applications remain under FDA review.

A second rig has been procured for the 1,300-metre Saskatchewan program, with C$975,000 allocated to drilling.

BBA will study Lion and Nisk Main using the September resource estimate, with capital costs and preliminary economics targeted for the first half of 2027.

The Oct. 5 sale leaves 38.3 million previously issued shares unsold as the company targets a £17 million Coinbase loan balance.

The proposed truck-to-rail handoff at Matagami still needs a commercial contract, with service pricing and upgrade contributions to be negotiated.

The 125-patient single-arm study had no control group, while Medtronic says U.S. payer coverage reaches 96% of commercial and Medicare insured lives.

Two unnamed inference customers extend earlier deals, with QumulusAI targeting capacity turnover in December 2026 and early 2027.

The FDA label covers previously untreated adults with no known 17p deletion after a 282-patient trial against chemoimmunotherapy.

Among 109 treated patients, the median response lasted 12.1 months; the single-arm cohort offers no direct efficacy comparison.

The GL1 hole lies about 100 metres southeast of earlier drilling; assays from ten more holes in the completed program remain pending.

The company says the agency has set no new action date, while its U.S. launch target remains conditional on approval.

Bitdeer's Oct. 3 update lists zero pure bitcoin holdings as of Oct. 2 but gives no sale price, proceeds or mining costs.

The Nevada lithium study assumes US$24,000 per tonne of lithium carbonate and US$2.77 billion in first-phase capital.

Rebisufligene etisparvovec won U.S. approval on Sept. 17; Ultragenyx gave no date for a European decision.

The Oct. 1 close follows a 25 million share proposal, but the completion notices give no final ownership percentage or cash proceeds to the parent.

State approvals cleared the Oct. 1 transfer of certain Ohio operations; AYR disclosed no cash proceeds or debt relief figure.

One petition is active and the other pending review; both would let Florida medical operators sell to adults if voters approve.

The TSX Venture company has issued US$10.5 million of secured convertible notes and will seek shareholder approval for preferred shares on Oct. 14.

SITC presentations will follow a three-year EVX-01 clinical update on Oct. 24; the 75% response rate was first reported in 2025.

Surrozen expects to dose DUET's first patient in Q4; clearance also meets a condition for a US$95.1M financing close around Oct. 20.

The first-line application is expected to be completed by year end; a separate monotherapy NDA has a Feb. 27, 2027 FDA target.

AstraZeneca or Daiichi Sankyo will sponsor the planned breast cancer study, with all three companies sharing trial costs and retaining drug rights.

The Oct. 1 filing attributes the joint termination to delayed closing and gives no figure for any termination payment.

Bezant targets at least 9,000 tonnes of plant throughput in October, with first saleable concentrate expected late in the month.

The estimate puts contained copper at 495,400 tonnes; the separate Selebi North resource calculation remains pending.

Northcliff says the Sept. 23-effective report makes no material change to August's results; it holds 88.5 per cent of the partnership that owns Sisson.

Gross margin reached about 48 per cent in the June half, while WISeQey shares are due to trade as WQEY on Oct. 5 after an ADS conversion.

The ARTG's Sept. 15 entry names Jupiter Research as manufacturer; Curaleaf also reports a Sept. 17 New Zealand WAND notification.

The AUTUS pulmonary valve can later be widened by catheter; the FDA cited a 62-child study and flagged longer-term risks.